🇺🇸 FDA

Intelligence · Patent portfolio

CORCEPT THERAPEUTICS Patents

Full USPTO pharma patent portfolio for CORCEPT THERAPEUTICS — grant dates, expiration, and drug cross-links.

Patents
120
Expiring ≤24m
3

Quick answer

CORCEPT THERAPEUTICS has 120 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 3 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 3

  1. US 12370188

    Formulations of dazucorilant, a glucocorticoid receptor modulator

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12370175

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12336985

    Methods for shrinking pituitary tumors

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12290551

    Methods for imaging and treatment of somatostatin-receptor positive tumors

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12285425

    Glucocorticoid receptor modulators to treat cervical cancer

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12263169

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12226412

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12226417

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12171760

    Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12152028

    Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12144812

    Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12139486

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12109272

    Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12102642

    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12097192

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12097210

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12098144

    Piperazine indazole glucocorticoid receptor antagonists

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12098141

    Bicyclic indazole glucocorticoid receptor antagonists

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12018001

    Pyrimidine cyclohexenyl glucocorticoid receptor modulators

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12005055

    Methods for shrinking pituitary tumors

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11969435

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11944617

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11925626

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11903945

    Methods of treating antipsychotic-induced weight gain with miricorilant

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11890289

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11793810

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11744837

    Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11684612

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11660295

    Glucocorticoid receptor modulators to treat cervical cancer

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11648245

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11642331

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11610666

    Systems and methods of managing treatment of a chronic condition by symptom tracking

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11590113

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11590135

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11576907

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11560379

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11542238

    Pyrimidine cyclohexenyl glucocorticoid receptor modulators

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11524013

    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11464764

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11389432

    Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11370789

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11327083

    Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11285145

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11268145

    Methods for treating Cushing's syndrome

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11234971

    Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11213526

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11202787

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11202784

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does CORCEPT THERAPEUTICS have?

120 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do CORCEPT THERAPEUTICS patents expire?

3 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.